Cyclin kinase inhibitors in breast cancer: From bench to bedside

被引：3
|
作者：
Torres G. [1 ]
Echavarría I. [1 ]
Lobo M. [1 ]
Márquez-Rodas I. [1 ]
Martin M. [1 ]
机构：
[1] Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, 28007 Madrid
来源：
Current Breast Cancer Reports | 2014年 / 6卷 / 2期
关键词：
Breast cancer; Cdk4; Cdk6; Cell cycle; Cyclin; Cyclin kinase inhibitors; Palbociclib; Targeted therapy;
D O I：
10.1007/s12609-014-0142-3
中图分类号：
学科分类号：
摘要：
A precise knowledge of cell-cycle machinery and its effect on tumorigenesis has led to the development of a large number of anticancer drugs targeting this pathway. In breast cancer research, the promising results of recent clinical trials of novel selective CDK-inhibitors, for example palbociclib, have generated high expectations for this field. This review gathers the results of the most recent clinical trials of CDK inhibitors for breast cancer, and outlines their potential as anticancer therapy. © Springer Science+Business Media 2014.
引用
收藏
页码：79 / 87
页数：8
相关论文
共 50 条
  • [21] Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside
    Maria João de Sousa
    Lorenzo Gervaso
    Monica Isabel Meneses-Medina
    Francesca Spada
    Omar Abdel-Rahman
    Nicola Fazio
    Current Oncology Reports, 2022, 24 : 715 - 722
  • [22] Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside
    de Sousa, Maria Joao
    Gervaso, Lorenzo
    Meneses-Medina, Monica Isabel
    Spada, Francesca
    Abdel-Rahman, Omar
    Fazio, Nicola
    CURRENT ONCOLOGY REPORTS, 2022, 24 (06) : 715 - 722
  • [23] MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
    Hardy-Werbin, Max
    del Rey-Vergara, Raul
    Alejandro Galindo-Campos, Miguel
    Moliner, Laura
    Arriola, Edurne
    CANCERS, 2019, 11 (10)
  • [24] Tirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside
    Olivieri, Jacopo
    Coluzzi, Sabrina
    Attolico, Imma
    Olivieri, Attilio
    THESCIENTIFICWORLDJOURNAL, 2011, 11 : 1908 - 1931
  • [25] A review of PARP inhibitors: from bench to bedside
    Underhill, C.
    Toulmonde, M.
    Bonnefoi, H.
    ANNALS OF ONCOLOGY, 2011, 22 (02) : 268 - 279
  • [26] MET inhibitors: translating from bench to bedside
    Mayor, Susan
    LANCET ONCOLOGY, 2011, 12 (01): : 14 - 14
  • [27] Aromatase inhibitors: from bench to bedside and back
    Geisler, Jurgen
    BREAST CANCER, 2008, 15 (01) : 17 - 26
  • [28] Rapamycine and mTOR inhibitors: from bench to bedside
    Pallet, N.
    Beaune, P.
    Legendre, C.
    Anglicheau, D.
    ANNALES DE BIOLOGIE CLINIQUE, 2006, 64 (02) : 107 - 115
  • [29] RTK Inhibitors in Melanoma: From Bench to Bedside
    Sabbah, Malak
    Najem, Ahmad
    Krayem, Mohammad
    Awada, Ahmad
    Journe, Fabrice
    Ghanem, Ghanem E.
    CANCERS, 2021, 13 (07)
  • [30] Aromatase inhibitors: from bench to bedside and back
    Jürgen Geisler
    Breast Cancer, 2008, 15 : 17 - 26
12345